Enzalutamide prostate cancer drug
C019/9775 Rights Managed
530 pixels on longest edge, unwatermarked
Request/Download high-res file
Uncompressed file size: 50.0MB
Downloadable file size: 2.3MB
Please login to use the price calculator
Credit: DR P. MARAZZI/SCIENCE PHOTO LIBRARY
Restrictions: Editorial use only
Caption: Enzalutamide prostate cancer drug. This new hormone therapy drug, developed by Medivation and marketed by Astellas, was approved for use in the USA in 2012. It has also been licensed for use in the UK. It is used in cases of advanced prostate cancer that are no longer responding to standard hormone therapy or chemotherapy.
Release details: Model release not required. Property release not available.
Keywords: 2013, 21st century, 40 mg, 40 milligram, adult, advanced, astellas, braille dots, brand, brandname, caucasian, clinic, display, displaying, doctor, drug, enzalutamide, hands, healthcare, hold, holding, hospital, human, male, man, mdv3100, medical, medicine, new, oncological, oncologist, oncology, one person, oral, packaging, packet, people, person, pharmaceutical, pharmaceutics, pharmacological, pharmacology, physician, prostate cancer, soft capsules, treatment, white, xtandi
Licence fees: A licence fee will be charged for any media (low or high resolution) used in your project.